Two pilots from the Air India group have produced non-negative outcomes in the first round of required psychoactive substance screening, according to sources. Their samples are now undergoing confirmatory analysis, and final results remain pending.
A non-negative finding indicates that the initial test detected a substance or marker needing further verification. It does not confirm that the pilots consumed any prohibited material. The follow-up test will determine if the result is accurate.
The cases emerged shortly after the airline group began mandatory testing for all pilots on August 13, prompted by an earlier incident on flight AI2379 from Phuket to Delhi. Around 300 to 400 pilots have completed the screening so far, with the process ongoing.
Sources indicated that two pilots have been identified in the initial round. Their samples are now under additional review to check for actual psychoactive substance use.
The broader testing program follows the August 4 event on AI2379, during which the Airbus A320 lost roughly 300 feet of altitude while cruising. The plane later stabilized and landed safely, though some passengers and crew sustained injuries.
Both pilots from that flight underwent screening afterward. The co-pilot showed no concerns, but the pilot-in-command required further checks and was later confirmed positive for marijuana. Both were removed from flight duties pending investigation.
The drug test forms only one element of the ongoing inquiry into the flight. Reports noted multiple system alerts, including hydraulic pressure warnings and autopilot disconnection. The Aircraft Accident Investigation Bureau continues to review the aircraft systems, flight data, and sequence of events. No determination has linked the positive test to the altitude loss.
Air India expanded the mandatory screening across its pilot group, including Air India Express, starting August 13. The effort exceeds standard random testing and targets prohibited substances at pilot bases and training sites. The two latest cases arose during this expanded program. The pilots remain under review until confirmatory results are available.
